Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study.

AIM: To evaluate the effectiveness and safety of retrograde transvenous obliteration (RTO) for the prevention of variceal rebleeding variceal rebleeding in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This multicentre retrospective study enrolled 79 patients with HCC who underwent RTO for the prevention of variceal rebleeding. Successful occlusion of the gastrorenal shunt and obliteration of the gastric varices were achieved in 74 patients, with a technical success rate of 93.7%. Of the remaining 74 patients (mean age, 64.9±10.3 years; 56 men), 66 (90.4%) had gastroesophageal varices and seven (9.6%) had isolated gastric varices. Thirty-two patients (43.8%) underwent balloon-occluded RTO, 40 patients (54.8%) underwent plug-assisted RTO, and one patient (1.4%) underwent coil-assisted RTO. No patients had major procedural complications. RESULTS: Rebleeding occurred in seven patients (9.6%) during the follow-up period. The 6-week and 1-year actuarial probabilities of patients remaining free of rebleeding were 90.8±3.6% and 88.6±4.1%, respectively. The median survival was 12.6 (95% confidence interval [CI] 8-17.3) months. The 6-week, 1-year, and 3-year actuarial probabilities of survival were 83.2±4.4%, 51.1±6.6%, and 32.7±7%, respectively. New or worsening ascites and oesophageal varices occurred in 12 (16.4%) and 13 patients (17.8%), respectively, during the follow-up period. Overt hepatic encephalopathy occurred in one patient (1.4%) during the follow-up period. The Child-Pugh score remained comparable to that at baseline at 1 and 3 months. CONCLUSION: RTO was effective and safe in preventing variceal rebleeding in patients with HCC.

Circulating interleukin 17 is increased in the acute stage of Kawasaki disease.

OBJECTIVES: During the acute phase, patients with Kawasaki disease (KD), an acute systemic vasculitis, demonstrate a drastic increase in serum interleukin-6 (IL-6), which parallels the duration of the fever. Recently, IL-17 has been reported to induce IL-6 production. The aim of this study was to elucidate the involvement of IL-17 in the pathogenesis of KD. METHODS: Serum samples were obtained from patients with KD (n=30) and normal controls (n=20), and the concentrations of IL-17 and IL-6 measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: Compared with the normal controls (2.08 +/- 2.14 pg/mL), serum IL-17 was markedly elevated in patients with acute KD (25.47 +/- 5.05 pg/mL): levels gradually decreased in the subacute phase (5.94 +/- 2.83 pg/mL). In the acute phase, levels of IL-6 were 83.52 +/- 19.12 pg/L, which correlated well with the serum levels of IL-17. CONCLUSION: These results suggest that IL-17 may be involved in the development of, or the effects of inflammation in KD.